Journal profile · MATHEMATICAL & COMPUTATIONAL BIOLOGY-STATISTICS & PROBABILITY
Statistics in Biopharmaceutical Research
ISSN 1946-6315 · Taylor and Francis Ltd. · UNITED STATES · Quarterly · Founded 2009
Statistics in Biopharmaceutical Research: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 1.54; JCR Q2 (journal website); hybrid open access; APC about USD 3,450; median 259 days to acceptance (81 articles, last 24 months); community-reported acceptance: 41%; 72 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Statistics in Biopharmaceutical Research is published by Taylor and Francis Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Statistical Methods in Clinical Trials, Advanced Causal Inference Techniques and Health Systems, Economic Evaluations, Quality of Life, together about 52.1% of its articles. Its main subfields are Statistics and Probability. (generated from OpenAlex topic counts and CAS ranking data)
Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems. Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome. Articles should include demonstrable evidence of the usefulness of this methodology (presumably by means of an application). The Editorial Board of SBR intends to ensure that the journal continually provides important, useful, and timely information. To accomplish this, the board strives to attract outstanding articles by seeing that each submission receives a careful, thorough, and prompt review. . ASA Statement on Justice, Equity, Diversity, and Inclusion (JEDI) The leadership of the American Statistical Association commits to strengthening our professional community by making it more just, equitable, d
From the journal's Aims & Scope
Research area (LetPub): MATHEMATICAL & COMPUTATIONAL BIOLOGY-STATISTICS & PROBABILITY
Editor-in-chief Weili HePublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Statistical Methods in Clinical TrialsMathematics30.9%
- Advanced Causal Inference TechniquesMathematics11.1%
- Health Systems, Economic Evaluations, Quality of LifeEconomics, Econometrics and Finance10.1%
- Optimal Experimental Design MethodsDecision Sciences10%
- Statistical Methods and Bayesian InferenceMathematics7.8%
- Statistical Methods and InferenceMathematics6.9%
- Meta-analysis and systematic reviewsDecision Sciences3.3%
- Biosimilars and Bioanalytical MethodsImmunology and Microbiology2.9%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Mathematical & Computational Biology | Zone 3 |
| Minor | Statistics & Probability | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Mathematical & Computational Biology | Zone 4 |
| Minor | Statistics & Probability | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Mathematical & Computational Biology | Zone 3 |
| Minor | Statistics & Probability | Zone 4 |
Top journal: noReview journal: no
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · best quartile · 2025
- CiteScore Q2 · 2025
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
Web of ScienceEmbasePublisher website
Other: BIOSIS Previews, EBSCOhost, Genamics JournalSeek, Clarivate Analytics, Biological Abstracts (Online), Biotechnology Citation Index (Online)
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 1.54LetPub ·
- Impact factor (publisher) 2025
- 1.6Publisher website ·
- 5-year impact factor (publisher) 2025
- 1.6Publisher website ·
- CiteScore 2026-06
- 3.2LetPub ·
- CiteScore (publisher) 2025
- 3.2Publisher website ·
- SJR 2026-06
- 0.87LetPub ·
- SJR (publisher) 2025
- 0.87Publisher website ·
- SNIP 2026-06
- 0.97LetPub ·
- SNIP (publisher) 2025
- 0.97Publisher website ·
- h-index
- 11LetPub ·
- h-index
- 40OpenAlex ·
- i10-index
- 219OpenAlex ·
- 2-year mean citedness
- 1.16OpenAlex ·
- Self-citation rate
- 25%LetPub ·
- Share of gold OA articles
- 9.76%LetPub ·
Volume
- Articles per year
- 59LetPub ·
- Downloads per year (publisher) 2025
- 99,000Publisher website ·
Articles by year OpenAlex count · 1,032 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 61 | 15 | 7 |
| 2025 | 72 | 16 | 53 |
| 2024 | 52 | 31 | 155 |
| 2023 | 73 | 31 | 302 |
| 2022 | 60 | 31 | 323 |
| 2021 | 81 | 34 | 703 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
259 daysMedian, submission to acceptance · P25–P75 168 days – 364 days
- Acceptance to online
- median 60 days (81 articles)
- Submission to online
- median 316 days
- Sample
- 81 articles with submission and acceptance dates (156 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- over 12 weeksLetPub ·
- Average acceptance (community reports)
- 41%LetPub ·
- Acceptance rate (publisher) 2025
- 39%Publisher website ·
- Submission to first decision 2025
- 33 daysPublisher website ·
- First decision after review 2025
- 46 daysPublisher website ·
- Acceptance to publication 2025
- 66 daysPublisher website ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| Publisher website | USD 3,450 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Policy excerpts from the journal's websiteOpen access, Peer review
- Open access Open access
If you choose not to publish open access in this journal, there is no APC. Model summary
Statistics in Biopharmaceutical Research is a hybrid open access journal that is part of the Taylor & Francis Open Select publishing program, giving you the option to publish open access. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research. Why choose open access? Increase the di…
Source ↗Publisher website ·- Peer review
Rigorous peer review for every open access article Model summary
Rigorous peer review for every open access article
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Taylor and Francis Ltd.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Quarterly
- Founded
- 2009
- ISSN
- 1946-6315
- Society / sponsor
- American Statistical Association
- Latest issue on the website
- Volume 18, Issue 3 (2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Statistics in Biopharmaceutical Research
What CAS zone is Statistics in Biopharmaceutical Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Statistics in Biopharmaceutical Research is in Zone 4 of Medicine, and in Zone 3 of the minor category Mathematical & Computational Biology / Statistics & Probability. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Statistics in Biopharmaceutical Research?
The latest impact factor listed by LetPub is 1.54; CiteScore 3.2, h-index 40.
How long does peer review take at Statistics in Biopharmaceutical Research?
Based on the dates recorded on 81 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 259 days (interquartile range 168–364 days); authors report an average review time of over 12 weeks; the community-reported acceptance is “41%”; the journal's website gives an acceptance rate of 39% (2025). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Statistics in Biopharmaceutical Research in?
The journal's website gives JCR Q2 (best quartile). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 4 of Medicine.
Which databases index Statistics in Biopharmaceutical Research?
According to LetPub and DOAJ records, Statistics in Biopharmaceutical Research is indexed in SCIE and Scopus. The journal's website also lists Web of Science and Embase; that list has not been checked against each database.
Is Statistics in Biopharmaceutical Research open access, and what is the APC?
Statistics in Biopharmaceutical Research is a hybrid journal. For open-access publication: APC about USD 3,450.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .